BioSpace News Archive

HepaTx, a pre-clinical stage biotechnology company dedicated to the development of transformative therapies for liver diseases, announced today that Julio Gutierrez, MD has joined their Clinical Advisory Board.

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, participated in the Piper Sandler Spring Biopharma Symposium being held in Boston, MA, Wednesday, May 17 through Thursday, May 18, 2023.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the promotion of John Mazzola to Chief Operating Officer.

Science Applications International Corp. announced the appointment of 35-year global technology veteran Toni Townes-Whitley as the company’s Chief Executive Officer, effective October 2, 2023.

Patient-centered, holistic, personalized medicine is the future of healthcare. One-size-fits-all healthcare approaches are in the past, according to Lisa McDonald

OncoSec Medical Incorporated announced the closing of its previously announced registered direct offering of 1,408,384 shares of its common stock, at a purchase price of $0.945 per share, priced at-the-market under Nasdaq rules.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 128,840 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023.

Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists in treating complex cardiac arrhythmias such as atrial fibrillation (AF), today announced that the U.S. Food and Drug Administration (FDA) has cleared Volta AF-Xplorer™, an AI companion designed for the assessment of complex AF and atrial tachycardia (AT) procedures.

Sebela Women’s Health Inc. today announced positive results of a Phase 3 study demonstrating that investigational Copper 175 mm2 IUD met the primary efficacy outcome measurement of prevention of pregnancy through 3 years of use, with a cumulative 3-year Pearl Index (number of pregnancies per 100 women over 1 year) of 0.96 (95% CI, 0.59-1.48) or 99% efficacy.